Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001628280-17-001118
Filing Date
2017-02-10
Accepted
2017-02-10 16:59:52
Documents
1

Document Format Files

Seq Description Document Type Size
1 SC 13G - AJ KAZIMI 2016 schedule13g-ajkazimi2016.htm SC 13G 76443
  Complete submission text file 0001628280-17-001118.txt   77938
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filed by) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G
SIC: 2834 Pharmaceutical Preparations

Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Subject) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: SC 13G | Act: 34 | File No.: 005-85205 | Film No.: 17594394
SIC: 2834 Pharmaceutical Preparations